MX2021008874A - Adn de extremo cerrado (ceadn) y uso en metodos de reduccion de la respuesta inmunitaria relacionada con tratamiento genico o de acido nucleico. - Google Patents
Adn de extremo cerrado (ceadn) y uso en metodos de reduccion de la respuesta inmunitaria relacionada con tratamiento genico o de acido nucleico.Info
- Publication number
- MX2021008874A MX2021008874A MX2021008874A MX2021008874A MX2021008874A MX 2021008874 A MX2021008874 A MX 2021008874A MX 2021008874 A MX2021008874 A MX 2021008874A MX 2021008874 A MX2021008874 A MX 2021008874A MX 2021008874 A MX2021008874 A MX 2021008874A
- Authority
- MX
- Mexico
- Prior art keywords
- immune response
- methods
- cedna
- nucleic acid
- close
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796450P | 2019-01-24 | 2019-01-24 | |
| US201962796417P | 2019-01-24 | 2019-01-24 | |
| US201962800303P | 2019-02-01 | 2019-02-01 | |
| US201962800285P | 2019-02-01 | 2019-02-01 | |
| US201962814424P | 2019-03-06 | 2019-03-06 | |
| US201962814414P | 2019-03-06 | 2019-03-06 | |
| US201962857542P | 2019-06-05 | 2019-06-05 | |
| PCT/US2020/015026 WO2020154645A1 (en) | 2019-01-24 | 2020-01-24 | Close-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008874A true MX2021008874A (es) | 2021-08-19 |
Family
ID=71735812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008874A MX2021008874A (es) | 2019-01-24 | 2020-01-24 | Adn de extremo cerrado (ceadn) y uso en metodos de reduccion de la respuesta inmunitaria relacionada con tratamiento genico o de acido nucleico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220119840A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3914717A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022518504A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210119416A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113412331A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020211457A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3127799A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA54826A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021008874A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202107922QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020154645A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020001593A (es) | 2017-08-09 | 2020-07-13 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y usos de las mismas. |
| JP2021511047A (ja) * | 2018-01-19 | 2021-05-06 | ジェネレーション バイオ カンパニー | 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス |
| CN108920903B (zh) * | 2018-07-09 | 2022-04-01 | 湘潭大学 | 基于朴素贝叶斯的LncRNA与疾病的关联关系预测方法及系统 |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| US20220175816A1 (en) * | 2019-04-18 | 2022-06-09 | University Of Massachusetts | Aim2 inhibitors and uses thereof |
| US20210371465A1 (en) * | 2020-03-26 | 2021-12-02 | Yale University | Method of using a tlr9 antagonist as an anti-inflammatory and anti-fibrotic agent |
| MX2023001109A (es) | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
| AU2021330936A1 (en) * | 2020-08-23 | 2023-05-04 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| CN112138164B (zh) * | 2020-09-25 | 2022-06-03 | 徐州医科大学 | Aim2在制备降低car-t治疗毒副作用的药物中的应用 |
| WO2022182792A1 (en) | 2021-02-23 | 2022-09-01 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| IL306038A (en) * | 2021-03-22 | 2023-11-01 | Massachusetts Inst Technology | Multicellular microRNA sensing with elemental erns to regulate multipolar gene expression in mammalian cells |
| JP2024540994A (ja) * | 2021-07-23 | 2024-11-06 | スパーク セラピューティクス インコーポレイテッド | 非ウイルス性dna送達のための方法および組成物 |
| AU2022211795A1 (en) * | 2021-08-06 | 2023-02-23 | Syte.Bio Inc. | Hairpin loop ended self-complementary double-stranded covalently closed linear dna vector, manufacturing system and process, and uses of said resulting dna vector |
| EP4396349A4 (en) * | 2021-09-02 | 2025-10-22 | Molecular Axiom Llc | COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION |
| CN114796216A (zh) * | 2022-01-04 | 2022-07-29 | 南京医科大学 | 甲氟喹在防治全身代谢性炎症疾病中的应用 |
| JP2025532680A (ja) * | 2022-09-20 | 2025-10-01 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 抗線維化マイクロrna組成物 |
| WO2024121814A1 (en) | 2022-12-09 | 2024-06-13 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
| KR20250155027A (ko) | 2023-02-21 | 2025-10-29 | 포세이다 테라퓨틱스, 인크. | Aav piggybac 트랜스포존 폴리뉴클레오티드 조성물 및 이의 사용 방법 |
| CN121532216A (zh) * | 2023-04-18 | 2026-02-13 | 赛仁生物技术公司 | 腺相关病毒载体组合物和使用方法 |
| IL327036A (en) | 2023-09-19 | 2026-05-01 | Poseida Therapeutics Inc | Compositions and methods for combining viral vectors |
| CN122341729A (zh) * | 2023-11-30 | 2026-07-03 | 赛诺菲 | 末端封闭的dna分子的纯化 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377898B2 (en) * | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| WO2013019623A2 (en) * | 2011-07-29 | 2013-02-07 | Fred Hutchinson Cancer Research Center | Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
| AU2015342968B2 (en) * | 2014-11-05 | 2021-05-27 | Selecta Biosciences, Inc. | Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog |
| IL261524B2 (en) * | 2016-03-03 | 2023-10-01 | Univ Massachusetts | End-capped linear double-stranded DNA for non-viral gene transfer |
| EP3468605A4 (en) * | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS |
-
2020
- 2020-01-24 KR KR1020217024528A patent/KR20210119416A/ko active Pending
- 2020-01-24 WO PCT/US2020/015026 patent/WO2020154645A1/en not_active Ceased
- 2020-01-24 AU AU2020211457A patent/AU2020211457A1/en not_active Abandoned
- 2020-01-24 MA MA054826A patent/MA54826A/fr unknown
- 2020-01-24 CN CN202080010834.4A patent/CN113412331A/zh active Pending
- 2020-01-24 SG SG11202107922QA patent/SG11202107922QA/en unknown
- 2020-01-24 MX MX2021008874A patent/MX2021008874A/es unknown
- 2020-01-24 CA CA3127799A patent/CA3127799A1/en active Pending
- 2020-01-24 EP EP20745787.0A patent/EP3914717A4/en active Pending
- 2020-01-24 US US17/424,199 patent/US20220119840A1/en not_active Abandoned
- 2020-01-24 JP JP2021542384A patent/JP2022518504A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3127799A1 (en) | 2020-07-30 |
| AU2020211457A1 (en) | 2021-09-09 |
| SG11202107922QA (en) | 2021-08-30 |
| US20220119840A1 (en) | 2022-04-21 |
| EP3914717A1 (en) | 2021-12-01 |
| JP2022518504A (ja) | 2022-03-15 |
| MA54826A (fr) | 2021-12-01 |
| CN113412331A (zh) | 2021-09-17 |
| WO2020154645A1 (en) | 2020-07-30 |
| EP3914717A4 (en) | 2022-11-16 |
| KR20210119416A (ko) | 2021-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021108755A3 (en) | Microdystrophin gene therapy constructs and uses thereof | |
| EP4089172A3 (en) | Multiple vector system and uses thereof | |
| WO2011150421A3 (en) | Recombinant bacterium to decrease tumor growth | |
| MX2025014318A (es) | Vector de adenovirus de chimpance util para la administracion de neoantigenos | |
| MX2015014423A (es) | Administración efectiva de genes grandes por vectores aav duales. | |
| WO2017218974A3 (en) | Treatment of amd using aav2 variant with aflibercept | |
| WO2016019144A3 (en) | Gene correction of scid-related genes in hematopoietic stem and progenitor cells | |
| ZA202006505B (en) | Micro rna expression constructs and uses thereof | |
| PH12020551235A1 (en) | Controlled expression of transgenes using closed-ended dna (cedna) vectors | |
| MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
| MX2020001282A (es) | Polipeptidos que tienen actividad trehalasa y uso de los mismos en proceso de produccion de productos de fermentacion. | |
| MX2020006065A (es) | Metodos y productos para la produccion y administracion de acido nucleico. | |
| MX2020000676A (es) | Composiciones y metodos para tratar beta-hemoglobinopatias. | |
| MY183703A (en) | Oncolytic adenovirus encoding a b7 protein | |
| AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
| BR112016028023A2 (pt) | Composições e métodos de administração de tratamentos para infecções virais latentes | |
| CA3057899A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
| EP4361279A3 (en) | Pathogen-resistant animals having modified cd163 genes | |
| WO2017059177A3 (en) | Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages | |
| EP3998341A3 (en) | Adenoviral vectors | |
| MX2020005663A (es) | Terapia genica para mucopolisacaridosis iii a. | |
| WO2019140116A3 (en) | Amplifiable rnas for therapeutic cell systems | |
| Leleux et al. | Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy | |
| PE20221123A1 (es) | Endonucleasa de escision dual encapsulada en lipidos para edicion de genes y adn | |
| MY198782A (en) | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |